Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer
Summary
Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer A drug candidate once shelved by Takeda Pharmaceutical (NYSE: TAK) has found new life within Roivant Sciences spinout Myovant as a potential once-daily oral hormone therapy for patients with advanced prostate cancer. The Brisbane, CA-based biotech company (MYSE: MYOV) reported Tuesday that the drug, relugolix, met the primary goal of a Phase 3 trial, lowering levels of testosterone to what’s known as “castrate levels” through 48 weeks for 96.7 percent of those receiving the investigational medicine. In addition to avoiding the flare phenomenon, Myovant is betting patients will find taking a daily pill preferable to receiving periodic injections. The most commonly reported adverse events among those receiving relugolix were hot flashes, fatigue, constipation, diarrhea, and joint pain. The year prior, Axovant Sciences (NASDAQ: AXON) ended its efforts to advance the neurodegeneration drug intepirdine, which it had acquired from GlaxoSmithKline (NYSE: [[ticker:GSK]), after it failed in clinical trials of dementia with Lewy bodies and of Alzheimer’s disease.
Classifications
AskAI Classifications
LabelsLinked Companies
